Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.30 -0.89 (-4.03%)
Streaming Delayed Price Updated: 11:21 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
33 34 Next >
News headline image
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
RADNOR, PA - April 11, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf... 
Via TheNewswire.com
Topics Fraud
News headline image
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
RADNOR, PA - April 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of... 
Via TheNewswire.com
Topics Fraud
News headline image
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions. 
Via MarketBeat
News headline image
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to... 
Via StockStory
Topics Supply Chain
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗
Via The Motley Fool
News headline image
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops ↗
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise. 
Via Stocktwits
Topics Government
News headline image
Sarepta Therapeutics Provides Update on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook. 
Via Benzinga
News headline image
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death ↗
The holds are temporary while the teenager's death is under investigation. 
Via Investor's Business Daily
Topics Death
News headline image
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings) ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.